Pinned post
Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space!
rdcu.be/dAr8w
@ProstateUKProfs @nubiosciences @NU_Cancer #glycotime
rdcu.be/dAr8w
@ProstateUKProfs @nubiosciences @NU_Cancer #glycotime